AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3881309
Drug: Metoclopramide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (two 10-mg capsules t.i.d.)
Trial: 488520
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules)
Trial: 29678170
Drug: Suture repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture repair group with dynamic augmentation and microfracture of the femoral notch
Trial: 27055679
Drug: 3% diquafosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diquafosol sodium ophthalmic solution (DQS)
Trial: 22167565
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) dosing strategies
Trial: 21425572
Drug: Xiongshao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiongshao Capsule (XSC)
Trial: 20124517
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg daily)
Trial: 15470330
Drug: Rifabutin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (300 mg daily)
Trial: 10223781
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral contraceptives only)
Trial: 2083081
Drug: Dermoval cream
RxNorm normalized name: clobetasol propionate Topical Ointment [Dermovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermoval cream
Trial: 2083081
Drug: Colorimetric parameters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorimetric parameters a* (redness) and L* (luminance)
Trial: 630211
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (combination and single-agent chemotherapy)
Trial: 30929590
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy (AT) for eight weeks
Trial: 30929590
Drug: Sham Art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham Art Therapy (mandala coloring group) for eight weeks
Trial: 23351071
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) therapy
Trial: 16504835
Drug: Demographic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic and clinical variables (age, duration of diabetes, insulin use, smoking history, hypertension, BMI, race, ethnicity, cholesterol levels, statin use)
Trial: 12946547
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg QD for 12 months
Trial: 12946547
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg QD for 12 months
Trial: 10989265
Drug: MDMA (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.7 mg/kg)
Trial: 7994166
Drug: Incremental intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental intravenous infusion of adrenaline (low, intermediate, high doses)
Trial: 2544291
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous GR43175
Trial: 429499
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sulpiride orally twice a day during the first 7 days of the puerperium
Trial: 429499
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sulpiride orally
Trial: 29136343
Drug: MOD-4023 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD-4023 (7.5 mg)
Trial: 29136343
Drug: MOD-4023 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD-4023 (all doses)
Trial: 17488174
Drug: Orff-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orff-based music therapy
Trial: 11920985
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) with exposure-based behavior therapy
Trial: 11920985
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) with nonexposure-based behavior therapy
Trial: 9760611
Drug: No capsule-bending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No capsule-bending ring (Control)
Trial: 6957155
Drug: Gemfibrozil (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (1200 mg daily)
Trial: 30894208
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg q2w + MTX
Trial: 30894208
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg q2w + MTX
Trial: 25733246
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg
Trial: 19428923
Drug: AMA1-C1 vaccine
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1-C1 vaccine with Alhydrogel
Trial: 9590971
Drug: Diclofenac‐potassium 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac‐potassium 50 mg
Trial: 9590971
Drug: Glafenine 200
RxNorm normalized name: Glafenine
DrugBank: Glafenine (DB08963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glafenine 200 mg
Trial: 9512220
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration
Trial: 28717347
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil group (n=10) consuming eight 300-mg EPA-rich fish oil softgel capsules per day for 8 weeks and continued for 5 days after exercise.
Trial: 28717347
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=11) consuming an equivalent number of placebo capsules.
Trial: 9158644
Drug: Warfarin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (control group)
Trial: 18318674
Drug: Antenatal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroid treatment (experimental group)
Trial: 18318674
Drug: No antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antenatal corticosteroid treatment (control group)
Trial: 16898074
Drug: Reference oral
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference oral solution (0.3 mg/100 ml)
Trial: 1894861
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous diltiazem infusion (10 to 15 mg/h)
Trial: 1894861
Drug: Combined diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diltiazem infusion (double-blind and open label)
Trial: 29171358
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone (crushed)
Trial: 17005043
Drug: Adalimumab (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (two doses, subcutaneously administered)
Trial: 8025209
Drug: Preventive therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive therapies for insulin-dependent diabetes (specific therapies not detailed)
Trial: 3344936
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Cladosporium herbarum
Trial: 27660194
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus structured, tailored group physical exercise (S + EX)
Trial: 22947426
Drug: Maribavir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maribavir (100 mg twice daily)
Trial: 18207225
Drug: Methamphetamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (3 mg, IV)
Trial: 21803113
Drug: Rivastigmine 3
RxNorm normalized name: rivastigmine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 3 mg
Trial: 15998547
Drug: Decubitus direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decubitus direct current treatment (DDCT)
Trial: 9431834
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg
Trial: 4015285
Drug: Oxprenolol 160
RxNorm normalized name: oxprenolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 160 mg
Trial: 1350485
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg
Trial: 25103305
Drug: Erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib treatment
Trial: 29968431
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/day)
Trial: 1729588
Drug: Psychiatric consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychiatric consultation advising physicians on treatment
Trial: 1729588
Drug: First-generation antidepressants
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antidepressants (amitriptyline, imipramine, doxepin)
Trial: 1729588
Drug: Newer antidepressants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antidepressants (nortriptyline, desipramine, trazodone, fluoxetine)
Trial: 6431572
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine, sublingually
Trial: 6431572
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate by inhalation
Trial: 28548626
Drug: Inactivated EV71
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated EV71 vaccine
Trial: 27323615
Drug: Ligustrazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine (2 mg/kg)
Trial: 20339154
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with pravastatin (40 mg once daily)
Trial: 20339154
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment without pravastatin
Trial: 11329096
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg orally in the morning and placebo in the evening
Trial: 27599329
Drug: Estriol 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol 0.1% (0.4 mg/d)
Trial: 25058146
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (3.0 g/day of NaCl) for 7 days
Trial: 25058146
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (18.0 g/day of NaCl) for 7 days
Trial: 25058146
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet with potassium supplementation (18.0 g/day of NaCl + 4.5 g/day of KCl) for 7 days
Trial: 22297625
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg IV plus ondansetron 4 mg IV (group DO)
Trial: 22297625
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg IV (group D)
Trial: 21175313
Drug: Imatinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (600 mg daily)
Trial: 21175313
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg daily) plus cytarabine (20 mg/m² daily on days 15-28)
Trial: 12488409
Drug: CVP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVP (cyclophosphamide 750 mg/m² and vincristine 1.2 mg/m² intravenously on day 1, prednisone 40 mg/m² orally on days 1 to 5, every 21 days)
Trial: 8587758
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 5% glucose water containing 4 g of regular instant coffee
Trial: 8587758
Drug: Baseline: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline: 500 ml of 5% glucose water
Trial: 2632448
Drug: Topical sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sulindac therapy
Trial: 26237828
Drug: WCR (insulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WCR (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol)
Trial: 23483023
Drug: Ensure preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensure preparation
Trial: 3310200
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg in the evening
Trial: 16634072
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment with Er:YAG laser (12.7 J/cm2)
Trial: 15292850
Drug: Rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation group (160 mg/d oral testosterone undecanoate for men, 80 mg/d for women, 563 kcal/d oral dietary supplements, exercise on ergometric bicycle 3 to 5 times a week)
Trial: 29523206
Drug: School-based humanistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based humanistic counselling (SBHC) delivered in up to 10 weekly sessions by a qualified counsellor.
Trial: 12665049
Drug: Two 80‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 80‐mg tablets twice daily
Trial: 12665049
Drug: Two 80‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 80‐mg tablets three times daily
Trial: 2654214
Drug: Twice-daily (nonoccluded)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily (nonoccluded) superpotent topical steroids for 2 weeks
Trial: 2669553
Drug: Topical glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticosteroids
Trial: 962352
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched control group (no steroid treatment)
Trial: 962352
Drug: Topical glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticosteroids (retesting after one month)
Trial: 25445851
Drug: Intermediate voice
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate voice therapy (from 4 to 8 weeks after injury)
Trial: 25445851
Drug: Delayed voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed voice therapy (at least 8 weeks after injury)
Trial: 11323139
Drug: Sequential spatial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential spatial discrimination for touch
Trial: 3127600
Drug: Keyhole-limpet hemocyanin
RxNorm normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keyhole-limpet hemocyanin (1 mg intracutaneously for immunization, followed by 10 mg monthly bladder instillations)
Trial: 3127600
Drug: Keyhole-limpet hemocyanin
RxNorm normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keyhole-limpet hemocyanin (10 mg monthly bladder instillations)
Trial: 3127600
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (20 mg monthly)
Trial: 30651321
Drug: TTP399 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTP399 (800 mg/day)
Trial: 15192923
Drug: Calculated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calculated insulin dose (CALC)
Trial: 15192923
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin dose (C)
Trial: 11275919
Drug: Long-acting antianginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting antianginal medications (long-acting diltiazem +/− nitroglycerin patches +/− atenolol)
Trial: 11275919
Drug: Optimal adjustment
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal adjustment of usual antianginal medications
Trial: 2839321
Drug: Psyllium 3.4
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium 3.4 g
Trial: 27166077
Drug: Psyllium 10.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium 10.2 g
Trial: 27166077
Drug: Psyllium 6.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium 6.8 g (Study 2)
Trial: 23895084
Drug: Trauma‐focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma‐focused cognitive behavioral therapy (TF‐CBT)
Trial: 23895084
Drug: Therapy as
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy as usual (TAU)
Trial: 20557327
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) administered subcutaneously every 2 weeks, titrated to maintain a target Hb level of 14.0±1.0 g/dL
Trial: 15877291
Drug: 1.2 g/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/min of glucose + 1.2 g/min of sucrose (H-GLU+SUC)
Trial: 12552030
Drug: Topiramate 500
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 500 mg/d
Trial: 18215213
Drug: Topiramate 200
RxNorm normalized name: topiramate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 200 mg/d
Trial: 15096395
Drug: Topiramate 50
RxNorm normalized name: topiramate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 50 mg/d
Trial: 9802630
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G diluted with lidocaine hydrochloride 1%
Trial: 23555624
Drug: internet-delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered Cognitive Behaviour Therapy (iCBT)
Trial: 19367435
Drug: 0.25% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% glyceryl trinitrate ointment and anal cryothermal dilators
Trial: 19367435
Drug: 0.4% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% glyceryl trinitrate ointment alone
Trial: 16957424
Drug: Telmisartan-HCTZ (80/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan-HCTZ (80/25 mg)
Trial: 16957424
Drug: Valsartan-HCTZ (160/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan-HCTZ (160/25 mg)
Trial: 1624025
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 3.75 mg
Trial: 24738111
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics (perphenazine, sulpiride, chlorpromazine)
Trial: 10546391
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (IPIC) lasting four days
Trial: 8756737
Drug: Hemodialysis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis therapy for over 50 months
Trial: 6869735
Drug: Thiopentone 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 4.5 mg/kg
Trial: 25048383
Drug: Albiglutide (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (once-weekly subcutaneous)
Trial: 25048383
Drug: Sitagliptin (daily)
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin (daily)
Trial: 17898654
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin (DaunoXome) 50 mg/m
Trial: 12488411
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cyclophosphamide, epirubicin, and vincristine (CEV)
Trial: 9296416
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine
Trial: 30559966
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT)
Trial: 2653757
Drug: Two different
RxNorm normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two different diabetes treatment regimens
Trial: 17132650
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no adenosine pretreatment)